Reply to: "Reporting of all cardiac medications and their outcome in COVID-19"
J Med Virol
.
2020 Sep;92(9):1421-1422.
doi: 10.1002/jmv.25868.
Epub 2020 Jun 3.
Authors
Hao Cheng
1
,
Yan Wang
1
,
Gui-Qiang Wang
1
2
3
Affiliations
1
Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.
2
The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, China.
3
Department of Liver Diseases, Peking University International Hospital, Beijing, China.
PMID:
32281653
PMCID:
PMC7262350
DOI:
10.1002/jmv.25868
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
COVID-19*
Coronavirus Infections* / epidemiology
Humans
Pandemics
Pneumonia, Viral* / epidemiology
SARS-CoV-2
Grants and funding
2017ZX10203202/13th Five-Year National Science and Technology Major Project/International
2018ZX10302206-001-007/13th Five-Year National Science and Technology Major Project/International
81870417/National Natural Science Foundation of China/International